Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis
PLOS ONE · 19.05.2023 · 18 (5) · e0286097
DOI: 10.1371/journal.pone.0286097 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 19.05.2023. Verfasst von Yue Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Qilu Medical University, Zibo, Shandong Province, China. Hauptthemen laut MEDLINE: Hyperthyroidism, Abortion, Spontaneous, Pregnancy Complications. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The purpose of this meta-analysis was to assess the safety of the anti-thyroid drugs (ATDs) propylthiouracil (PTU) and methimazole (MMI) in the treatment of hyperthyroidism during pregnancy.
Method
From inception until June 2, 2022, all available studies were searched in PubMed, Web of Science, Cochrane, EBSCO, Embase, Scopus, and CNKI.
Result
Thirteen articles satisfying the inclusion criteria were examined. Our meta-analysis indicated that pregnant women treated with MMI had a higher risk of congenital anomalies than those treated with PTU (OR 0.80, 95%CI 0.69–0.92, P = 0.002, I 2 = 41.9%). Shifting between MMI and PTU during pregnancy did not reduce the risk of birth defects compared to PTU alone (OR 1.18, CI 1.00 to 1.40, P = 0.061, I 2 = 0.0%). There were no statistically significant differences in hepatotoxicity (OR 1.54, 95%CI 0.77–3.09, P = 0.221, I 2 = 0.0%) or miscarriage (OR 0.89, 95%CI 0.72–1.11, P = 0.310, I 2 = 0.0%) between PTU and MMI exposure.
Conclusion
The study confirmed propylthiouracil is a safer alternative to methimazole for treating hyperthyroidism in pregnant women, and it is appropriate to treat maternal thyroid disease with PTU during the first trimester of pregnancy. However, it is not clear whether switching between propylthiouracil and methimazole is a better option than treating PTU alone during pregnancy. Further studies on this matter may be needed to develop new evidence-based guidelines for the treatment of pregnant women with hyperthyroidism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Nursing, Qilu Medical University, Zibo, Shandong Province, China.
ORCID-Profile: Yanyan Men
Zitieren
APA
Liu, Y., Li, Q., Xu, Y., Chen, Y., & Men, Y. (2023). Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis. PLOS ONE, 18(5), e0286097. https://doi.org/10.1371/journal.pone.0286097
Vancouver
Liu Y, Li Q, Xu Y, Chen Y, Men Y. Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis. PLOS ONE. 2023;18(5):e0286097. doi:10.1371/journal.pone.0286097
BibTeX
@article{Liu2023,
author = {Liu, Yue and Li, Qianqian and Xu, Yang and Chen, Yixin and Men, Yanyan},
title = {Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {5},
pages = {e0286097},
doi = {10.1371/journal.pone.0286097}
}
EUVIMED